Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Cinoxacine" patented technology

Method for detecting related substances of moxifloxacin hydrochloride bulk drug

The invention relates to the technical field of drug analysis and detection, in particular to a method for detecting related substances in moxifloxacin hydrochloride bulk drugs. According to the detection method provided by the invention, the separation efficiency of the known impurity (impurity F) can be improved, and the separation degree between the main component and the adjacent impurity can reach 1.5 or above; in addition, a solvent formula is optimized, so that a test sample is more stable, and the detection method is more accurate; the detection accuracy is improved, and the recovery rate is controlled within the range of 93-102%.
Owner:TIANJIN CHASE SUN PHARM CO LTD

Liquid chromatography detection method for enantiomers in moxifloxacin hydrochloride with high separation degree

The invention discloses a high performance liquid chromatography (HPLC) detection method for enantiomers in moxifloxacin hydrochloride with high separation degree, and belongs to the technical field of medicine detection. The method aims at solving the problems that in the prior art, the leading edge of a main component peak is serious, and the detection accuracy and good peak pattern under the conditions of high separation degree and low content are difficult to meet at the same time, and the adoption of an expensive chiral chromatographic column is avoided. According to the detection method, chiral resolution is realized on a conventional high performance liquid chromatograph by adopting a reversed-phase chromatographic column (such as terminated octadecylsilane chemically bonded silica as a filler). According to the core technical scheme, the unique mobile phase composition is as follows: a water phase contains 0.54 g / L of zinc acetate and 1.17 g / L of L-valine, 1ml of diethylamine is creatively added, and the pH value is adjusted to 5.6 by using dilute sulfuric acid; and an organic phase adopts a methanol-ethanol mixed solution (15: 8) with a specific ratio. And finally, mixing the water phase and the organic phase according to the volume ratio of 77: 23. Under optimal chromatographic conditions (the column temperature is 40 DEG C and the detection wavelength is 295 nm), the method can realize efficient separation between moxifloxacin hydrochloride and enantiomers, the separation degree is greater than 4.5, and the detection accuracy of trace isomers can be realized. A methodological verification result shows that the method is high in sensitivity (the detection limit is 0.0096%, and the quantitation limit is 0.024%), and has a good linear relationship (a correlation coefficient rgt; and the accuracy is good (the recovery rate is between 80.0% and 120.0%). The method can be used for qualitative and quantitative analysis of the moxifloxacin hydrochloride bulk drug and enantiomers in the moxifloxacin hydrochloride preparation.
Owner:CHONGQING PHARMACEUTICAL VALLEY PHARMACEUTICAL CO LTD

Preparation method of moxifloxacin hydrochloride crystal form II large-particle crystal

PendingCN121471215AOrganic chemistry methodsCinoxacineAqueous ethanol
The invention relates to the technical field of medicine crystallization, and discloses a preparation method of moxifloxacin hydrochloride crystal form II large-particle crystals, which comprises the following steps: S1, dissolving moxifloxacin tartrate in an ethanol water solution; s2, sequentially adding concentrated hydrochloric acid and moxifloxacin hydrochloride crystal form II rod-like seed crystals, and stirring to grow the crystals; s3, concentrated hydrochloric acid is continuously added in batches, and stirring and crystal growing are performed once after each batch of concentrated hydrochloric acid is added; the temperature is maintained at 30-60 DEG C during the S2 and S3; and S4, cooling, carrying out crystal growth, and separating out a product, thereby obtaining the moxifloxacin hydrochloride crystal form II large-particle crystal. By adopting the preparation method disclosed by the invention, the obtained moxifloxacin hydrochloride crystal form II crystal has a thick rod-shaped morphology and is relatively large and uniform in size.
Owner:ZHEJIANG APELOA KANGYU PHARMA +1

Moxifloxacin nano drug delivery system as well as preparation method and application thereof

The invention discloses a moxifloxacin nano drug delivery system as well as a preparation method and application thereof, and the moxifloxacin-loaded infected microenvironment lipase response nano drug delivery system is constructed on the basis of a comprehensive strategy of drug-assistant synergistic sensitization and antibiosis, improvement of permeability of a bacterial outer membrane, inhibition of activity of a bacterial efflux pump and removal of a biofilm. The sensitivity of moxifloxacin to multi-drug-resistant pseudomonas aeruginosa is enhanced, the pathogenicity of bacteria is reduced, and the risks of infection recurrence and drug resistance are reduced while the infection clearance rate is increased. And the antibiotic adjuvant adopts natural biodegradable epsilon-polylysine, so that the side effect of lung inhalation is reduced, and the biological safety of the nano-drug delivery system is improved.
Owner:GUANGXI MEDICAL UNIVERSITY

Gel eye drops containing bromfenac sodium and moxifloxacin hydrochloride as well as preparation method and application of gel eye drops

PendingCN121971385AOrganic active ingredientsSenses disorderSodium bromfenacOcular inflammation
The invention discloses gel eye drops containing bromfenac sodium and moxifloxacin hydrochloride as well as a preparation method and application of the gel eye drops, and belongs to the technical field of medicines. Comprising the following raw materials in parts by weight: 0.8-1.2 parts of bromfenac sodium, 0.8-6 parts of moxifloxacin hydrochloride, 15-30 parts of a gel matrix, 3-15 parts of sodium hyaluronate, 8-12 parts of an osmotic pressure regulator, 7.0-9.0 parts of citric acid, 0.02-0.05 part of sodium citrate and 950-1050 parts of purified water. The bromfenac sodium and the moxifloxacin hydrochloride are compounded, and the gel matrix, the sodium hyaluronate, the osmotic pressure regulator, the citric acid, the sodium citrate and the purified water are matched, so that the compound gel eye drops which are free of preservatives, low in irritation, good in stability, capable of improving the bioavailability of drugs and capable of achieving anti-inflammatory and antibacterial synergistic interaction are achieved, and eye inflammation can be effectively treated.
Owner:SHANGHAI WOLI BIOLOGICAL TECH DEV CO LTD

Preparation method of moxifloxacin hydrochloride intermediate

The invention discloses a preparation method of a moxifloxacin hydrochloride intermediate with high yield, high purity and low cost, and aims to overcome the technical defects of low resolution yield, need of additional acid addition, single solvent system, complex resolution agent recovery process and limited salifying efficiency in the prior art. According to the method, cis-8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3. 0] nonane (a compound as shown in a formula I) is taken as a raw material, N-acetylphenylalanine (including L-type and D-type) is taken as a resolving agent, acid does not need to be additionally added in a water-alcohol-ester ternary solvent system, efficient resolution of the enantiomer is directly realized through a salt forming reaction, and the yield of the enantiomer is increased. And the high-purity diazabicyclo compounds shown in the formulas IIIa and IIIb can be obtained without a refining step. The resolution yield can reach 90% or above, the recovery process of the resolving agent is simple and efficient, the recovery rate is larger than or equal to 95%, the resolving agent can be stably and circularly applied for five times or above, the resolution yield is still larger than or equal to 90% after the resolving agent is applied, the comprehensive production cost is reduced by 40%-60% compared with the prior art, and the method has outstanding industrial application advantages.
Owner:CHONGQING SHENGHUAXI PHARMA CO LTD +1

A colorimetric fluorescent probe for copper ions and synthesis and application thereof

ActiveCN117126139BConvenient Quantitative Detectionconvenient inspectionOrganic chemistryFluorescence/phosphorescenceCinoxacineMoxifloxacin
The application discloses a colorimetric copper ion fluorescent probe and synthesis and application thereof, which has a fluorophore and a copper ion recognition group, wherein the copper ion recognition group is one of commercial drugs of norfloxacin, levofloxacin, moxifloxacin and gatifloxacin. The copper ion fluorescent probe can be used for qualitative and colorimetric detection of copper ions, and is especially used in the fields of solution / cell / tissue / living body imaging, biological labeling or sensing.
Owner:NANTONG UNIV

Green synthesis method of moxifloxacin hydrochloride

PendingCN121342825AOrganic chemistryNonanePtru catalyst
The invention discloses a green synthesis method of moxifloxacin hydrochloride, which comprises the following steps: under a heating condition, reacting moxifloxacin cyclization ester with moxifloxacin ((S, S)-2, 8-diazabicyclo [4, 3, 0] nonane) in a solvent, alkali and catalyst system to obtain moxifloxacin ester, and then carrying out hydrolysis one-pot method in an acidic system to obtain the moxifloxacin hydrochloride. The moxifloxacin hydrochloride is directly prepared. The invention provides a green synthesis method of moxifloxacin hydrochloride. According to the green synthesis method, moxifloxacin is obtained through direct reaction of moxixane cyclization ester and moxixane. According to the method, the moxifloxacin serving as a target product is synthesized by taking the moxixane cyclization ester as a raw material without forming a chelate compound with boric acid ester and directly reacting with the moxixane through a one-pot method, no three wastes are generated in the preparation process, and the method has the advantages of short reaction steps, mild conditions, high yield and the like.
Owner:SHANGHAI ECUST BIOMEDICINE CO LTD +1

An ophthalmic composition, its method of preparation and use

PendingCN122440631AEscherichia coliMoraxella catarrhalis
The present application relates to the field of ophthalmic drugs, and particularly relates to an ophthalmic composition, a preparation method and application thereof, the ophthalmic composition comprising a compound as shown in formula I, an osmotic pressure regulator, a pH regulator and water for injection; the pH value of the ophthalmic composition is 4.0-6.0; the concentration of the compound as shown in formula I is 0.1-3.0% w / v, and the concentration of the osmotic pressure regulator is 0.3-10.0% w / v; the antibacterial activity against Streptococcus pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis is 2-8 times that of levofloxacin and moxifloxacin hydrochloride; the antibacterial activity against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Pseudomonas aeruginosa is also strong, and is equivalent to that of levofloxacin and moxifloxacin hydrochloride; the irritation is small, the light stability and high-temperature stability are good, the quality and drug safety are guaranteed, and the application value is good.
Owner:成都天兴致远生物科技有限公司

A method for removing boron from moxifloxacin hydrochloride and a method for preparing pure moxifloxacin hydrochloride

ActiveCN113321652BOrganic chemistryDivinylbenzeneBorate ion
The application provides a boron removal method of moxifloxacin hydrochloride and a preparation method of pure moxifloxacin hydrochloride, and belongs to the technical field of medicine preparation. In the application, LSC-800 resin is used for adsorbing and removing boric acid under the condition that the pH value is 8-9. The LSC-800 resin is a macroporous structure chelating resin which is crosslinked by styrene and divinylbenzene and has N-methylglucosamine groups. The polyol group part of the LSC-800 resin can generate complex anions with boric acid groups, and the amine group part of the LSC-800 resin can capture the generated complex anions as anion exchange groups, so that the boric acid ions in the boric acid-containing moxifloxacin hydrochloride can be selectively adsorbed, and the boric acid ions can be effectively removed. The results of the examples show that no boric acid is detected in the obtained moxifloxacin hydrochloride by using the boron removal method.
Owner:SHANDONG LUKANG PHARMA